SCHEMBL974802

SCHEMBL974802

O=C(O)c1ccccc1-c1ccccc1N=Nc1ccc(O)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDE P14735 1/20 0.77
KMT2A Q03164 7/20 0.56
MEN1 O00255 6/20 0.56
MAPT P10636 3/20 0.56
MYC P01106 1/20 0.52
NPC1 O15118 1/20 0.52
GAA P10253 4/20 0.47
NPSR1 Q6W5P4 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
TDP1 Q9NUW8 3/20 0.44
THRB P10828 2/20 0.44
PSMD14 O00487 1/20 0.44
HSP90AA1 P07900 1/20 0.44
MMP2 P08253 1/20 0.44
MAPK1 P28482 1/20 0.44
HNF4A P41235 1/20 0.44
TRPA1 O75762 1/20 0.43
ALDH1A1 P00352 2/20 0.43
CYP2C9 P11712 2/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5704809 0.90 IDE (0.60) IDEKMT2AMEN1MAPTMYC
SCHEMBL29401042 0.87 IDE (1.00) IDEKMT2AMEN1MAPTMYC
SCHEMBL453285 0.87 IDE (1.00) IDEKMT2AMEN1MAPTMYC
SCHEMBL453284 0.87 IDE (1.00) IDEKMT2AMEN1MAPTMYC
SCHEMBL12100493 0.87 IDE (1.00) IDEKMT2AMEN1MAPTMYC
SCHEMBL623529 0.85 MEN1 (0.70) IDEKMT2AMEN1MAPTMYC
SCHEMBL1252583 0.84 IDE (0.66) IDEKMT2AMEN1MAPTMYC
SCHEMBL3860617 0.78 CYP3A4 (0.47) IDEKMT2AMAPTMYCGAA
SCHEMBL10992403 0.77 IDE (0.70) IDEKMT2AMEN1MAPTMYC
SCHEMBL21501069 0.77 IDE (0.70) IDEKMT2AMEN1MAPTMYC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3137905-A1 METHOD OF ISOLATING A TARGET CELL IBA GmbH (DE) 2017-03-08 EP claimed
US-20170052176-A1 METHOD OF ISOLATING A TARGET CELL IBA LIFESCIENCES GMBH (DE) 2017-02-23 US claimed
WO-2015166049-A1 METHOD OF ISOLATING A TARGET CELL IBA GMBH (DE) 2015-11-05 WO claimed
EP-1769247-A1 BIOTIN RECOGNITION SENSORS AND HIGH-THROUGHPUT ASSAYS Molecular Probes, Inc. (US) 2007-04-04 EP claimed
US-20050208598-A1 Biotin recognition sensors and high-throughput assays MOLECULAR PROBES, INC. 2005-09-22 US claimed
WO-2005080989-A1 BIOTIN RECOGNITION SENSORS AND HIGH-THROUGHPUT ASSAYS MOLECULAR PROBES, INC. (US) 2005-09-01 WO claimed
EP-0414848-B1 BIOCOMPATIBLE MATERIALS COMPRISING ALBUMIN-BINDING DYES EATON JOHN W (US) 1995-10-11 EP claimed
EP-0414848-A4 BIOCOMPATIBLE MATERIALS COMPRISING ALBUMIN-BINDING DYES 1992-12-16 EP claimed
US-5073171-A Solid polymeric body incorporating an albumin-binding dye to form a protective coating; anticoagulants; antiinflammatory agents EATON JOHN W (US) 1991-12-17 US claimed
EP-0414848-A1 BIOCOMPATIBLE MATERIALS COMPRISING ALBUMIN-BINDING DYES. EATON JOHN W (US) 1991-03-06 EP claimed
WO-1990007950-A1 BIOCOMPATIBLE MATERIALS COMPRISING ALBUMIN-BINDING DYES EATON JOHN W (US) 1990-07-26 WO claimed
EP-4180811-B1 METHODS OF ISOLATING A BIOLOGICAL ENTITY CELL COPEDIA GMBH (DE) 2025-04-09 EP disclosed
US-12195556-B2 Reversible protein multimers, methods for their production and use LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) 2025-01-14 US disclosed
US-12181440-B2 Nitrogen-driven desorption by a diazirine NORTHEASTERN UNIVERSITY (US) 2024-12-31 US disclosed
US-20240329039-A1 METHODS OF ISOLATING A BIOLOGICAL ENTITY Cell.Copedia GmbH (DE) 2024-10-03 US disclosed
WO-1990007950-A1 BIOCOMPATIBLE MATERIALS COMPRISING ALBUMIN-BINDING DYES EATON JOHN W (US) 1990-07-26 WO disclosed
EP-0218962-B1 IMPROVED BIOTINYLATED PEROXIDASE MILES INC. (US) 1990-01-24 EP disclosed
US-4724203-A IMMUNOHISTOCHEMICAL MEASUREMENT MILES LABORATORIES, INC. (US) 1988-02-09 US disclosed
US-4656252-A Amidobiotin compounds useful in a avidin-biotin multiple layering process GIESE ROGER W 1987-04-07 US disclosed
US-4116633-A Globulin test PITMAN-MOORE, INC. (US) 1978-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12195556-B2 Reversible protein multimers, methods for their production and use CD4, CD74, MICA IDE 2772/4885KMT2A 3065/4885MEN1 3716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.